Want to see ARMP full AI Analyst Report?
ARMP Stock Chart & Stats
$4.66
$0.06(1.29%)
At close: 4:00 PM EDT
$4.66
$0.06(1.29%)
Day’s Range― - ―
52-Week Range$2.40 - $16.34
Previous CloseN/A
Volume56.99K
Average Volume (3M)213.69K
Market Cap
$189.63M
Enterprise Value$692.03
Total Cash (Recent Filing)$23.95M
Total Debt (Recent Filing)$313.95M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Nov 18, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.30
Shares Outstanding37,181,980
10 Day Avg. Volume216,533
30 Day Avg. Volume213,691
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.04
Price to Sales (P/S)46.41
P/FCF Ratio-8.65
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$17.50Price Target Upside275.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.81
Revenue Forecast (FY)$2.20M
Bulls Say, Bears Say
Bulls Say
AP-SA02 Is Advancing Toward A Pivotal Phase 3 TrialSubmission of the pivotal protocol and responses to FDA feedback indicate meaningful clinical and regulatory progress. Advancing AP-SA02 toward Phase 3 could improve the company’s development risk profile and create a clearer path toward potential commercialization.
FDA Agreement Establishes A Pediatric Development PathwayThe agreed pediatric plan removes an important regulatory uncertainty before a potential biologics license submission. It also provides a framework to expand AP-SA02 into children with serious resistant infections, broadening the candidate’s eventual addressable market.
Non-dilutive Government Funding Supports Late-stage DevelopmentGovernment funding helps finance Phase 3 preparation without the immediate dilution associated with equity issuance. Continued DoD support also validates strategic interest in phage therapeutics and provides resources for advancing the lead program through a costly development stage.
Bears Say
Negative Equity And Meaningful Debt Weaken Financial FlexibilityNegative equity reduces the balance-sheet cushion available to absorb further losses, while meaningful debt increases financial obligations. Together, these conditions may constrain strategic flexibility and raise the likelihood that future funding could be expensive or dilutive.
Persistent Cash Burn Creates Ongoing External Funding DependenceThe company continues to consume substantial cash while funding clinical development and has not yet established self-sustaining operations. Continued negative operating and free cash flow means additional capital will likely be needed to maintain programs and reach commercial milestones.
Limited Revenue Scale And Deep Losses Remain Major Operating RisksARMP has not yet demonstrated earnings power or a durable commercial revenue base. Its high cost structure relative to revenue leaves profitability dependent on successful clinical execution and eventual product approval, increasing vulnerability to delays, trial setbacks, or funding constraints.
Armata Pharmaceuticals News
ARMP FAQ
What was Armata Pharmaceuticals Inc’s price range in the past 12 months?
Armata Pharmaceuticals Inc lowest stock price was $2.40 and its highest was $16.34 in the past 12 months.
What is Armata Pharmaceuticals Inc’s market cap?
Armata Pharmaceuticals Inc’s market cap is $189.63M.
When is Armata Pharmaceuticals Inc’s upcoming earnings report date?
Armata Pharmaceuticals Inc’s upcoming earnings report date is Nov 18, 2026 which is in 86 days.
How were Armata Pharmaceuticals Inc’s earnings last quarter?
Armata Pharmaceuticals Inc released its earnings results on Aug 12, 2026. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.445 by $0.175.
Is Armata Pharmaceuticals Inc overvalued?
According to Wall Street analysts Armata Pharmaceuticals Inc’s price is currently Undervalued.
Does Armata Pharmaceuticals Inc pay dividends?
Armata Pharmaceuticals Inc does not currently pay dividends.
What is Armata Pharmaceuticals Inc’s EPS estimate?
Armata Pharmaceuticals Inc’s EPS estimate is -0.41.
How many shares outstanding does Armata Pharmaceuticals Inc have?
Armata Pharmaceuticals Inc has 37,181,980 shares outstanding.
What happened to Armata Pharmaceuticals Inc’s price movement after its last earnings report?
Armata Pharmaceuticals Inc reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.445. Following the earnings report the stock price went up 11.833%.
Which hedge fund is a major shareholder of Armata Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ARMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Armata Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.50 (275.54% Upside)
$17.50 (275.54% Upside)
Blogger Sentiment
Bearish
ARMP Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
87.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-20.00%
Trailing 12-Months
Company Description
Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
ARMP Stock 12 Month Forecast
Average Price Target
$17.50
▲(275.54% Upside)
Technical Analysis
Ownership Overview
0.60% Insiders
1.34% Mutual Funds
6.81% Other Institutional Investors
88.67% Public Companies and
Individual Investors